In a move that has sent shockwaves of excitement through the biotech community, Soleno Therapeutics (NASDAQ: SLNO, Up approx. +40% on Thursday) has successfully secured FDA approval for VYKAT XR, the first-ever treatment for hyperphagia in Prader-Willi syndrome (PWS). This rare genetic…